JP Morgan Reiterates Overweight Rating on Aktis Oncology, Inc. (AKTS)

Market Context

Aktis Oncology, Inc. operates in the Healthcare sector. The stock currently trades at $25.18 with a market capitalization of $1.1B. The stock has gained 20350.8% over the past 52 weeks.

Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Aktis Oncology, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Aktis Oncology, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 14, 2026	JP Morgan	Overweight	N/A
Jun 16, 2026	Raymond James	Strong Buy	N/A
Jun 02, 2026	HC Wainwright & Co.	Buy	N/A
Apr 29, 2026	William Blair	Outperform	N/A
Mar 31, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View AKTS Stock Page